LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

Home・Akciju saraksts・Guardant Health Inc

Guardant Health Inc

Slēgts

SektorsVeselības aprūpe

126.95 -2.27

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

125.2

Max

129.77

Galvenie mērījumi
By Trading Economics
Ienākumi	16M -112M
Pārdošana	20M 302M
EPS	-0.45
Peļņas marža	-37.152
Darbinieki	2,490
EBITDA	18M -101M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt (spēcīgs)
Prognoze 12 mēnešiem	+5.2% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 29. jūl.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	5B 17B
Iepriekšējā atvēršanas cena	129.22
Iepriekšējā slēgšanas cena	126.95

Ziņu noskaņojums

By Acuity

50%

154 / 344 Rangs Healthcare

Guardant Health Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 3. jūn. 23:22 UTC

Peļņas

Galvenie tirgus virzītāji

Broadcom Shares Slide Despite Jump in 2Q Revenue on AI Chip Demand -- Update

2026. g. 3. jūn. 23:09 UTC

Karstas akcijas

Stocks to Watch: Broadcom, CrowdStrike, PVH, Petco

2026. g. 3. jūn. 20:51 UTC

Peļņas

Costco Reports 15% Sales Growth in May

2026. g. 3. jūn. 20:43 UTC

Peļņas

Broadcom 2Q Revenue Climbs on AI Chip Demand

2026. g. 3. jūn. 23:48 UTC

Tirgus saruna

Nikkei May Fall Amid Renewed Concerns About Iran Conflict -- Market Talk

2026. g. 3. jūn. 23:48 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 3. jūn. 23:35 UTC

Tirgus saruna

Oil Futures Fall on Possible Technical Correction -- Market Talk

2026. g. 3. jūn. 23:15 UTC

Tirgus saruna

Peļņas

Five Below, Broadcom and Crowdstrike Fall Despite Solid Results -- Market Talk

2026. g. 3. jūn. 22:08 UTC

Karstas akcijas

After-Hours Stocks to Watch: CrowdStrike, Broadcom, Five Below -- WSJ

2026. g. 3. jūn. 21:54 UTC

Tirgus saruna

Correction to Oil Futures Rise on Concerns About U.S.-Iran Talks Article on June 1

2026. g. 3. jūn. 21:18 UTC

Peļņas

Broadcom's Non-AI Semiconductor Revenue Rose 6% in 2Q, CEO Says

2026. g. 3. jūn. 21:15 UTC

Peļņas

Broadcom CEO: Google Partnership Continues to Be 'Very Substantial'

2026. g. 3. jūn. 21:13 UTC

Peļņas

Broadcom CEO Expects AI Semiconductor Revenue Growth to Continue in Fiscal 2028

2026. g. 3. jūn. 21:13 UTC

Peļņas

Broadcom Continues to Expect AI Semiconductor Revenue of More Than $100B in 2027, CEO Says

2026. g. 3. jūn. 21:12 UTC

Peļņas

Broadcom Expects AI Semiconductor Revenue of $56B This Year, CEO Says

2026. g. 3. jūn. 21:09 UTC

Peļņas

Broadcom CEO: Networking Made Up Almost 40% of AI Revenue in 2Q

2026. g. 3. jūn. 21:03 UTC

Peļņas

Broadcom Stock Falls After Earnings. Here's Why. -- Barrons.com

2026. g. 3. jūn. 20:50 UTC

Tirgus saruna

Tech, Media & Telecom Roundup: Market Talk

2026. g. 3. jūn. 20:43 UTC

Peļņas

CrowdStrike Stock Falls Despite Earnings Beat -- Barrons.com

2026. g. 3. jūn. 20:39 UTC

Iegādes, apvienošanās, pārņemšana

Bill Ackman's Pershing Square Set To Make $600 Million on Universal Stake -- 4th Update

2026. g. 3. jūn. 20:37 UTC

Iegādes, apvienošanās, pārņemšana

Bill Ackman's Pershing Square Set To Make $600 Million on Universal Stake -- 3rd Update

2026. g. 3. jūn. 20:35 UTC

Peļņas

Broadcom Stock Falls Despite Record Results -- Barrons.com

2026. g. 3. jūn. 20:21 UTC

Iegādes, apvienošanās, pārņemšana

Bill Ackman's Pershing Square Set To Make $600 Million on Universal Stake -- 2nd Update

2026. g. 3. jūn. 20:17 UTC

Peļņas

Broadcom 2Q Semiconductor Solutions Revenue $15B >AVGO

2026. g. 3. jūn. 20:17 UTC

Peļņas

Broadcom Sees 3Q Semiconductor Revenue From AI $16B >AVGO

2026. g. 3. jūn. 20:15 UTC

Iegādes, apvienošanās, pārņemšana

Bill Ackman's Pershing Square Set To Make $600 Million on Universal Stake -- Update

2026. g. 3. jūn. 20:15 UTC

Peļņas

Broadcom 2Q Adj EPS $2.44 >AVGO

2026. g. 3. jūn. 20:15 UTC

Peļņas

Broadcom 2Q EPS $1.91 >AVGO

2026. g. 3. jūn. 20:15 UTC

Tirgus saruna

Global Commodities Roundup: Market Talk

2026. g. 3. jūn. 20:15 UTC

Peļņas

Broadcom 2Q Rev $22.19B >AVGO

Salīdzinājums

Cenas izmaiņa

Guardant Health Inc Prognoze

Cenas mērķis

By TipRanks

5.2% augšup

Prognoze 12 mēnešiem

Vidējais 136.94 USD 5.2%

Augstākais 160 USD

Zemākais 120 USD

Pamatojoties uz 17 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Guardant Health Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

17 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 17 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Guardant Health Inc — pēdējo 3 mēnešu laikā.

Noskaņojums

By Acuity

154 / 344 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Guardant Health Inc

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research; and with ConcertAI to form first data-as-a-service that integrates clinical and tumor profiling data to accelerate cancer therapy research and development. The company was incorporated in 2011 and is headquartered in Palo Alto, California.